Possible effect of genetic background in thrombophilia genes on clinical severity of patients with coronavirus disease-2019: A prospective cohort study


  • Ozlem Sezer Department of Medical Genetics, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
  • Ozgur Gunal Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
  • Recai Aci Department of Medical Genetics, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
  • Adem Keskin Department of Biochemistry, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey




COVID-19, FVL, MTHFR, PAI-1, polymorphism, thrombophilia


Background and objective: Thrombotic and microangiopathic effects have been reported in Coronavirus Disease-2019 (COVID-19) patients. In the present study, we aimed to examine the relationship between hereditary thrombophilia factors and the clinical picture severity of COVID-19 patients.

Methods: Ninety COVID-19 patients were included and grouped according to the severity to three groups: severe/critical (n=30), mild/moderate (n=30) and asymptomatic (n=30). Hereditary thrombophilia genetic markers [prothrombin (FII) G20210A, factor V Leiden (FVL) G1691A, factor XIII (FXIII) V34L, methylene tetrahydrofolate reductase (MTHFR) A1298C and C677T, and plasminogen activator inhibitor-1 (PAI-1) 4G & 5G] were genotyped for all patients.

Results: Seventeen (18.9%) patients had the polymorphism 4G/4G PAI-1 and 48 (53.3%) had 4G/5G. In addition, the heterozygous GA FVL, MTHRF677CT, and MTHRF1298AC polymorphisms were detected in 11 (12.2%), 26 (28.9%), and 38 (42.2%) patients, respectively. The rate of severe/critical patients with PAI 4G/5G gene polymorphism was higher than the asymptomatic+moderate/mild patients, and the rate of severe/critically ill patients with PAI 4G/4G polymorphism was found to be lower than the asymptomatic+moderate/mild patients. No difference was evidenced between the distribution of deceased and survivors of the genotype groups.

Conclusions: In the present study, we found that heterozygous 4G/5G PAI-1 polymorphism is associated with critical or severe COVID-19 picture, and that FVL, MTHFR, FXIII, and prothrombin polymorphisms were not directly related to COVID-19 severity.


Metrics Loading ...


Download data is not yet available.


A Girolami et al. “Prothrombin: Another clotting factor after FV that is involved both in bleeding and thrombosis”. Clin Appl Thromb Hemost 24(6) (2018), pp. 845–849. DOI: 10.1177/1076029618770741. DOI: https://doi.org/10.1177/1076029618770741

A K Ghosh and D E Vaughan. “PAI-1 in tissue fibrosis”. J Cell Physiol 227(2) (2012), pp. 493–507. DOI: 10.1002/jcp.22783. DOI: https://doi.org/10.1002/jcp.22783

A Kiraz et al. “Investigation of the relationship between inherited thrombophilia and novel coronavirus pneumonia”. Future Virol 16(5) (2021), pp. 341–345. DOI: 10.2217/fvl-2020-0395. DOI: https://doi.org/10.2217/fvl-2020-0395

B L Levin and E Varga. “MTHFR: Addressing genetic counseling dilemmas using evidence-based literature”. J Genet Couns 25(5) (2016), pp. 901–911. DOI: 10.1007/s10897-016-9956-7. DOI: https://doi.org/10.1007/s10897-016-9956-7

D E Vaughan. “PAI-1 and atherothrombosis”. J Thromb Haemost 3(8) (2005), pp. 1879–1883. DOI: 10.1111/j.1538-7836.2005.01420.x. DOI: https://doi.org/10.1111/j.1538-7836.2005.01420.x

D Giannis, I A Ziogas, and P Gianni. “Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past”. J Clin Virol 127 (2020), pp. 104362–104362. DOI: 10.1016/j.jcv.2020.104362. DOI: https://doi.org/10.1016/j.jcv.2020.104362

D Wu and X O Yang. “Dysregulation of pulmonary responses in severe COVID-19”. Viruses 13(6) (2021). DOI: 10.3390/v13060957. DOI: https://doi.org/10.3390/v13060957

E Campello et al. “Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients”. Thromb Res 156 (2017), pp. 20–22. DOI: 10.1016/j.thromres.2017.05.025. DOI: https://doi.org/10.1016/j.thromres.2017.05.025

E H Federici and H Al-Mondhiry. “High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A”. Thromb Res 182 (2019), pp. 75–78. DOI: 10.1016/j.thromres.2019.07.030. DOI: https://doi.org/10.1016/j.thromres.2019.07.030

F Zhou, T Yu, R Du, et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 395(10229) (2020), pp. 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

H A Rothan and S N Byrareddy. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak”. J Autoimmun 109 (2020), pp. 102433–102433. DOI: 10.1016/j.jaut.2020.102433. DOI: https://doi.org/10.1016/j.jaut.2020.102433

J A Stefely, B B Christensen, T Gogakos, et al. “Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism”. Am J Hematol 95(12) (2020). DOI: 10.1002/ajh.25979. DOI: https://doi.org/10.1002/ajh.25979

J Altinisik et al. “Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients”. Clin Appl Thromb Hemost 14(4) (2008), pp. 415–420. DOI: 10.1177/1076029607306404. DOI: https://doi.org/10.1177/1076029607306404

J M Connors. “Thrombophilia testing and venous thrombosis”. N Engl J Med 377(12) (2017), pp. 1177–1187. DOI: 10.1056/NEJMra1700365. DOI: https://doi.org/10.1056/NEJMra1700365

L Xie, Q Wu, Q Lin, et al. “Dysfunction of adaptive immunity is related to severity of COVID-19: a retrospective study”. Ther Adv Respir Dis 14 (2020), pp. e1753466620942129. DOI: 10.1177/1753466620942129. DOI: https://doi.org/10.1177/1753466620942129

M Karimi, S Haghpanah, and A Shahsavani. “Prevalence and clinical features of COVID-19 in Iranian patients with congenital coagulation disorders”. Blood Transfus 18(5) (2020), pp. 413–414. DOI: 10.2450/2020.0223-20.

M Karst, J Hollenhorst, and J Achenbach. “Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia?” Med Hypotheses 144 (2020), pp. 110234–110234. DOI: 10.1016/j.mehy.2020.110234. DOI: https://doi.org/10.1016/j.mehy.2020.110234

M Panigada, N Bottino, P Tagliabue, et al. “Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis”. J Thromb Haemost 18(7) (2020), pp. 1738–1742. DOI: 10.1111/jth.14850. DOI: https://doi.org/10.1111/jth.14850

N Kipshidze, G Dangas, C J White, et al. “Viral coagulopathy in patients with COVID-19: Treatment and care”. Clin Appl Thromb Hemost 26 (2020), pp. 1076029620936776–1076029620936776. DOI: https://doi.org/10.1177/1076029620936776

R Liu, Y Wang, J Li, et al. “Decreased T cell populations contribute to the increased severity of COVID-19”. Clin Chim Acta 508 (2020), pp. 110–114. DOI: 10.1016/j.cca.2020.05.019. DOI: https://doi.org/10.1016/j.cca.2020.05.019

R M Camire. “A new look at blood coagulation factor V”. Curr Opin Hematol 18(5) (2011), pp. 338–342. DOI: 10.1097/MOH.0b013e3283497ebc. DOI: https://doi.org/10.1097/MOH.0b013e3283497ebc

Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 Infection): Scientific Committee Study. 2020. URL: https://www.teb.org.tr/versions_latest/1240/13nisansbrehberi.

S Cui et al. “Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia”. J Thromb Haemost 18(6) (2020), pp. 1421–1424. DOI: 10.1111/jth.14830. DOI: https://doi.org/10.1111/jth.14830

S Duga, R Asselta, and M L Tenchini. “Coagulation factor V”. Int J Biochem Cell Biol 36(8) (2004), pp. 1393–1399. DOI: 10.1016/j.biocel.2003.08.002. DOI: https://doi.org/10.1016/j.biocel.2003.08.002

S Lancellotti, Maria Basso, and Raimondo De Cristofaro. “Congenital prothrombin deficiency: an update”. Semin Thromb Hemost 35(4) (2009), pp. 367–381. DOI: 10.1055/s-0033-1348948. DOI: https://doi.org/10.1055/s-0029-1225759

S Middeldorp, M Coppens, T F Van Haaps, et al. “Incidence of venous thromboembolism in hospitalized patients with COVID-19”. J Thromb Haemost 18(8) (2020), pp. 1995–2002. DOI: 10.1111/jth.14888. DOI: https://doi.org/10.1111/jth.14888

S Wan, Q Yi, S Fan, et al. “Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients”. Br J Haematol 189(3) (2020), pp. 428–437. DOI: 10.1111/bjh.16659. DOI: https://doi.org/10.1111/bjh.16659

T Iwaki, T Urano, and K Umemura. “PAI-1, progress in understanding the clinical problem and its aetiology”. Br J Haematol 157(3) (2012), pp. 291–298. DOI: 10.1111/j.1365-2141.2012.09074.x. DOI: https://doi.org/10.1111/j.1365-2141.2012.09074.x

T Matsuyama et al. “An aberrant STAT pathway is central to COVID-19”. Cell Death Differ 27(12) (2020), pp. 3209–3225. DOI: 10.1038/s41418-020-00633-7. DOI: https://doi.org/10.1038/s41418-020-00633-7

Y Zhang, W Cao, W Jiang, et al. “Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients”. J Thromb Thrombolysis 50(3) (2020), pp. 580–586. DOI: 10.1007/s11239-020-02182-9. DOI: https://doi.org/10.1007/s11239-020-02182-9

Y Zhou, V Sinnathamby, Y Yu, et al. “Folate intake, markers of folate status and oral clefts: An updated set of systematic reviews and meta-analyses”. Birth Defects Res 112 (2019), pp. 1699–1719. DOI: 10.1002/bdr2.1827. DOI: https://doi.org/10.1002/bdr2.1827




How to Cite

Possible effect of genetic background in thrombophilia genes on clinical severity of patients with coronavirus disease-2019: A prospective cohort study. (2022). Baghdad Journal of Biochemistry and Applied Biological Sciences, 3(03), 183-199. https://doi.org/10.47419/bjbabs.v3i03.141